Connect with us

Biotechnology

3 Pharma Stocks To Watch In December 2019

A. Lawrence

Published

on

make money with biotech stocks now

Are Biotech Stocks On Your Watch List This Month?

Biotech stocks have been one of the best performing sectors this quarter. Over the past 2 months or so, many companies in the sector have come up with highly innovative products. There’ve also been pivotal phase trial updates and key milestones hit by small and large companies alike. That has consequently created significant value for the market.

top biotech stocks to watch list

Considering the fact that the sector is going to continue to improve in the coming year, it is important for investors to track the biotech sector very closely. Here is a quick look at two biotech stocks that should be added to the watch lists by investors.

Biotech Stocks To Watch: Sernova Corp. (TSX:SVA) (OTC:SEOVF) Presents Strong Phase Data

Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes

This was presented just a few months ago and could show exactly why Sernova (TSX:SVA) (OTC:SEOVF) has started generating more interest across the medical community and public market as wellSernova (TSX:SVA) (OTC:SEOVF)’s Cell Pouch™ transplanted with islet cells showed initial safety, as well as key efficacy measures, including:

  1. Glucose stimulated C-peptide
  2. Insulin production
  3. Clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness.

There was specifically an 87.5% reduction in hypoglycemic events from baseline collected over a two-week monitoring period. These data were so strongly delivered that it has firmly warranted advancing its clinical trials to more patients with type-1 diabetes.

Biotech Stocks To Watch: Novavax Gains Momentum

The first biotech stock to track closely is that of Novavax, Inc. (NASDAQ:NVAX). The company does not have any development coming up immediately but it the new year that could prove to be a pivotal time. In the new year, the company is expected to provide data from the late-stage clinical trial of its product NanoFlu, which is meant to treat seasonal flu.

The company believes that the data from the trial will prove once and for the market as well as to the regulators that NanoFly is ready to hit the market. The results from the phase three study are expected to be published at some point in the first quarter of 2020 and investors should watch developments closely.

Biotech Stocks To Watch: Can-Fite BioPharma Soars on Earnings

The other biotech stock that is worth tracking is that of Can-Fite BioPharma Ltd., (NYSE: CANF). The company announced its financial results for the first nine months of 2019 today and that resulted in a significant rally in the stock this morning. The net losses for the period were reduced by as much as 151.6% to $7.8 million while the revenues stood at $1.8 million which reflects a decline of 48.6%. In addition to that, the company revealed that it has been given permission by the FDA for the Phase 3 liver cancer study design.

Other updates included the receipt of $750,000 for a distribution deal with South Korea’s Piclidenoson and a compassionate use program in Israel. Can-Fite also entered into a partnership with Univo Pharmaceuticals to create CBD based assays and pharmaceuticals. The stock rocketed by 42% on Friday’s trading session on the back of the updates.

biotechnology stocks to buy now

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 11, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading
Click to comment

Biotechnology

2 Biotech Stocks To Watch Before Next Week

A. Lawrence

Published

on

stock_price_medicine

Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.

Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.

Biotech Stocks To Watch: Marinus Pharmaceuticals

The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS)  which has made significant gains on Wednesday on the back of an important announcement.

top biotech stocks to buy

On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.

Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.

Biotech Stocks To Watch: Diffusion Pharmaceuticals

top biotech stocks to buy now

The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.

It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.

Continue Reading

Biotechnology

StockPrice.com Subscribers WIN BIG!

Jon Phillip

Published

on

stock price WINNING

We owe you a BIG congratulations. The whole point of StockPrice.com is to bring you important information, first. Sure we send emails out every day on top trending articles and news but we also bring periodic reports on certain companies.

Earlier this year we brought you a full report on a company, PharmaCyte Biotech (PMCB).

Since that report, we’ve watched as PharmaCyte evolved into what it has become today: a biotech powerhouse on the verge of presenting its treatment to the FDA!

Stock Price Subscribers Saw The Full PMCB 90%+ Breakout From August – December; Congratulations! Click Here to Read Our Original Report

This is a great thing for subscribers and we’ve got more featured reports coming! How do you get these reports first?


STEP 1: Make Sure Our Email Address Is In Your Whitelist Address Book So Nothing Gets Lost In Spam

STEP 2:Take Out Your Cell Phone And Text “STOCKPRICE” to 63566. Even If You Miss An Email, We Send Out Updates Directly To Your Cell Phone In Real Time

Again, congratulations to everyone and make sure you stay tuned for our next Stock Price Exclusive Report!




Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading

Biotechnology

Are These Biotech Stocks To Buy Or Sell Right Now?

Joe Samuel

Published

on

medical stocks to watch now

2 Biotech Stocks Rally But Can That Continue?

One of the sectors that have proven to be a consistently steady performer in the stock market over the past few years is the biotech sector. Hence, it is not really a surprise that investors are almost always on the lookout for the next big thing among biotech stocks.

However, it is important to note that even though biotech is a prosperous sector, an investor needs to put in his fair share of research in order to discover potential winners. Here is a look at two biotech stocks that could be tracked by investors closely over the coming days.

Vistagen Therapeutics Gains As FDA Grants fast track designation for PH94B

top biotech stocks to watch list

The first one to consider is that Vistagen Therapeutics Inc (VTGN Stock Report) that made significant gains after the company made a major announcement with regards to one of its products. The company announced on Tuesday that its social anxiety disorder product PH94B has been granted fast track designation by the United States Food and Drug Administration.

As everyone knows, it is a significant milestone for the company as it tries to bring the product to the market and the market naturally reacted positively to the news. The stock shot up by as much as 44.60% on the back of the news and has emerged as one of the biotech stocks that could be tracked closely today.

Iterum Therapeutics up 280% in 3 Weeks

The other biotech stock that has made a significant move this morning is that of Iterum Therapeutics PLC (NASDAQ:ITRM). On Tuesday, the stock rallied by as much as 22% but there was no material news with regards to the company that could have triggered that sort of a rally. However, last month, the company had made a major announcement about one of its products.

Iterum announced that it had completed enrolment of patients for the study of Sulopenem for Resistant Enterobacteriaceae (SURE). The medicine meant for treating complicated urinary tract infections. The stock has rallied by as much as 270% since the news broke back on November 18.

make money with biotech stocks now

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com